Evidence map›Paper›PMID 41350796›Full record

ReviewAAPS PharmSciTech2025

Efficacy of Novel Drug Delivery Systems for Insulin Administration and Technological Advances in Diabetes Mellitus: Review.

Hossamaldeen Bakrey, Mazin Aboobaida Abdalla Abdelaziz, Fatehalrahman Faris Magbool, Alaa Bakrey, Omer Ibrahim A Omer, Israa Abdelrahim, Abdulkadir Abdu

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hossamaldeen BakreyDepartment of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India.ORCID http://orcid.org/0009-0002-6298-4992
Mazin Aboobaida Abdalla AbdelazizRaghavendra Inst. Pharmaceutical Education and Research (RIPER)Affiliated to, JNT University Anantapur, Anantapur, AP, India.ORCID http://orcid.org/0000-0001-9893-1126
Fatehalrahman Faris MagboolRed Sea University, Port Sudan, 33315, Sudan.ORCID http://orcid.org/0000-0003-0411-4120
Alaa BakreyDepartment of Clinical Pharmacy, University of Khartoum, Khartoum, 11111, Sudan.ORCID http://orcid.org/0009-0006-1617-4082
Omer Ibrahim A OmerDepartment of Pharmacy Practice, College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, 530003, India.ORCID http://orcid.org/0000-0002-1620-7319
Israa AbdelrahimUniversity of Medical Science and Technology, Khartoum, 11111, Sudan.
Abdulkadir AbduDepartment of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India. gauraabdu61@gmail.com.ORCID http://orcid.org/0009-0003-7617-7574

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is a clinical syndrome characterized by disturbance in carbohydrate, fat and protein metabolism due to either insulin deficiency or insulin resistance. Oral medications and insulin injections have typically been the conventional delivery modalities of diabetes treatment for both type 1 and patients with advanced type 2 diabetes. In spite of this, these treatments have some drawbacks, including low efficacy, unwanted side effects and the possibility of hypoglycemia. New developments in medication delivery techniques, such as insulin pumps, inhalers and patches, have been made with the intention of enhancing the efficacy of the treatment. Insulin pumps allow for precise and flexible administration of insulin, which, in turn, reduces the number of episodes of low blood sugar. The use of inhalers provides a non-invasive alternative that facilitates rapid glycemic management and increases patient satisfaction. Currently in the process of being developed, insulin patches provide a means of administering insulin that is both simple and painless. In this review, we investigate the efficacy, safety and practicability of various technological breakthroughs, such as insulin pumps, smart insulin pens and continuous glucose monitoring systems. In addition to this, it addresses the challenges that are preventing a wider acceptance, such as the costs, the availability and the requirements for training. In order to enhance patient outcomes and usher in a new era of diabetes care that is increasingly driven by technology, the report places a strong emphasis on the necessity of continued research and innovation.

Indexed as

Diabetes MellitusDrug Delivery SystemsHypoglycemic AgentsInsulinBlood GlucoseDiabetes Mellitus, Type 2HumansInsulin Infusion SystemsBlood GlucoseHypoglycemic AgentsInsulinadvancement technologydiabetesdrug delivery Inhalersinsulin patchesinsulin pumpsnovel medicines

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.